Stratos Wealth Advisors LLC Takes $2.02 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Stratos Wealth Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 83,475 shares of the biopharmaceutical company's stock, valued at approximately $2,024,000. Stratos Wealth Advisors LLC owned approximately 0.07% of Catalyst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $27,000. Park Square Financial Group LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $29,000. Farther Finance Advisors LLC boosted its holdings in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Sound Income Strategies LLC bought a new stake in Catalyst Pharmaceuticals in the first quarter worth $64,000. Finally, GAMMA Investing LLC boosted its holdings in Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Six investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $32.83.

Catalyst Pharmaceuticals Stock Down 0.2%

CPRX stock traded down $0.04 during mid-day trading on Friday, reaching $21.81. 1,378,856 shares of the stock traded hands, compared to its average volume of 1,133,110. Catalyst Pharmaceuticals, Inc. has a 52 week low of $15.34 and a 52 week high of $26.58. The business has a 50-day moving average of $23.51 and a two-hundred day moving average of $22.88. The firm has a market capitalization of $2.66 billion, a PE ratio of 13.89, a P/E/G ratio of 0.88 and a beta of 0.66.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the sale, the insider directly owned 68,873 shares in the company, valued at $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Preethi Sundaram sold 1,600 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider directly owned 41,081 shares of the company's stock, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 247,924 shares of company stock valued at $5,879,369 over the last 90 days. Corporate insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.